Artiva Biotherapeutics, Inc. ARTV Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$87.07M-21.4% | -$83.87M-28.3% | -$79.19M-29.2% | -$75.13M-131% | -$71.72M-176% | ||
| $2.64M+6.6% | $2.6M+6.8% | $2.55M+5.6% | $2.51M+7.3% | $2.47M— | ||
| $6.36M-16.6% | $6.82M-2.3% | $7.42M+19.8% | $7.69M+36.1% | $7.63M— | ||
| —— | $0+100% | -$569K-68.6% | -$569K-171% | -$819K-589% | ||
| $1.01M— | -$760K— | —— | —— | —— | ||
| -$1.07M— | $2M— | -$1.35M— | $629K— | —— | ||
| —— | $191K+253% | $120K+186% | -$292K-112% | -$348K— | ||
| —— | —— | —— | —— | —— | ||
| -$77.86M-30.2% | -$76.75M-39.5% | -$76.68M-50.2% | -$69.09M-37.6% | -$59.79M— | ||
| $2.32M+104% | $2.59M+303% | $2.23M+83.7% | $1.73M+33.1% | $1.14M— | ||
| $32.8M-82.6% | $44.88M-74.5% | $52.19M-70.4% | $182.38M+301% | $188.49M— | ||
| $103.87M+49.8% | $110.87M+96.8% | $100.82M+82.7% | $83.6M+52.6% | $69.35M— | ||
| $68.76M+157% | $63.41M+153% | $46.41M+138% | -$100.5M-1,361% | -$120.27M— | ||
| —— | —— | —— | —— | —— | ||
| $132K— | $132K— | $131K— | $137K— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$10.64M+39.5% | -$14.52M-9.5% | -$30.17M-202% | -$5.58M— | -$17.6M— | ||
| $1.36M-49.7% | $1.88M-19.7% | $2.63M+66.2% | $2.93M— | $2.7M— | ||
| —— | —— | -$29K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0+100% | $0+100% | -$977K+67.1% | -$3.33M-317% | ||
| $103.87M+49.8% | $110.87M+96.8% | $100.82M— | $83.6M— | $69.35M— | ||
| $132K— | $132K— | $131K— | $137K— | —— | ||
| —— | $0— | $20K— | $2.62M— | —— | ||
| —— | —— | —— | —— | -$134K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $54.1M— | $108.21M— | $162.31M— | ||
| —— | —— | —— | —— | $442K— | ||
| -$80.18M-31.6% | -$79.34M-42.5% | -$78.91M-51.0% | -$70.81M-37.5% | -$60.92M— | ||
| -$80.18M-31.6% | -$79.34M-42.5% | -$78.91M-51.0% | -$70.81M-37.5% | -$60.92M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Artiva Biotherapeutics, Inc. generate?
- Artiva Biotherapeutics, Inc. (ARTV) generated -$77.9M in operating cash flow over the trailing twelve months.
- What is Artiva Biotherapeutics, Inc.'s free cash flow?
- After $2.3M of capital expenditures, Artiva Biotherapeutics, Inc.'s free cash flow was -$80.2M over the trailing twelve months, down 31.6% year over year.
- Where does Artiva Biotherapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Artiva Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.